MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck

Cancer

Volumn 117, Issue 7, 2011, Pages 1454-1462

  Langevin, Scott M ^a,b   Stone, Roslyn A ^b   Bunker, Clareann H ^a,b   Lyons Weiler, Maureen A ^a,c,d   Laframboise, William A ^a,c,d   Kelly, Lori ^a,c,d   Seethala, Raja R ^a,c   Grandis, Jennifer R ^a,c   Sobol, Robert W ^a,b,c   Taioli, Emanuela ^e  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

epigenetics; head and neck cancer; miR 137; miRNA; prognosis

Indexed keywords

MICRORNA; MICRORNA 137; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LARYNX CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; OVERALL SURVIVAL; PHARYNX CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RNA METHYLATION; SQUAMOUS CELL CARCINOMA; TUMOR LOCALIZATION; TUMOR VOLUME;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 79952822271     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25689     Document Type: Article

References (56)

1. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP., Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005; 114: 806-816. (Pubitemid 40344442)
2. Argiris A, Karamouzis MV, Raben D, Ferris RL., Head and neck cancer. Lancet. 2008; 371: 1695-1709. (Pubitemid 351671886)
3. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM., MicroRNA expression and function in cancer. Trends Mol Med. 2006; 12: 580-587. (Pubitemid 44780201)
4. Chang KW, Liu CJ, Chu TH, et al. Association between high miR-211 microRNA expression and the poor prognosis of oral carcinoma. J Dent Res. 2008; 87: 1063-1068.
5. Chang SS, Jiang WW, Smith I, et al. MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer. 2008; 123: 2791-2797.
6. Childs G, Fazzari M, Kung G, et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol. 2009; 174: 736-745.
7. Connolly E, Melegari M, Landgraf P, et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol. 2008; 173: 856-864.
8. Dalmay T., MicroRNAs and cancer. J Intern Med. 2008; 263: 366-375. (Pubitemid 351342684)
9. Fabbri M, Ivan M, Cimmino A, Negrini M, Calin GA., Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther. 2007; 7: 1009-1019.
10. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007; 67: 8699-8707. (Pubitemid 47437445)
11. Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 2008; 47: 1955-1963. (Pubitemid 351952843)
12. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007; 120: 1046-1054. (Pubitemid 46214304)
13. Pierson J, Hostager B, Fan R, Vibhakar R., Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol. 2008; 90: 1-7.
14. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 2006; 9: 435-443. (Pubitemid 43832188)
15. Schulte JH, Horn S, Otto T, et al. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer. 2008; 122: 699-704. (Pubitemid 350308967)
16. Silber J, Lim DA, Petritsch C, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008; 6: 14.
17. Takakura S, Mitsutake N, Nakashima M, et al. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci. 2008; 99: 1147-1154. (Pubitemid 351676626)
18. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI., Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res. 2008; 14: 2588-2592.
19. Zhao JJ, Lin J, Yang H, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008; 283: 31079-31086.
20. Camps C, Buffa FM, Colella S, et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008; 14: 1340-1348. (Pubitemid 351413913)
21. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M., MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg. 2008; 12: 2171-2176.
22. Gallardo E, Navarro A, Vinolas N, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009; 30: 1903-1909.
23. Kaddar T, Chien WW, Bertrand Y, et al. Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation. Leuk Res. 2009; 33: 1217-1223.
24. Katada T, Ishiguro H, Kuwabara Y, et al. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol. 2009; 34: 537-542.
25. Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H., Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res. 2007; 67: 10117-10122. (Pubitemid 350070782)
26. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES., Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008; 54: 1696-1704.
27. Qian B, Katsaros D, Lu L, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat. 2009; 117: 131-140.
28. Schepeler T, Reinert JT, Ostenfeld MS, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 2008; 68: 6416-6424.
29. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004; 64: 3753-3756. (Pubitemid 38697282)
30. Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008; 14: 2348-2360.
31. Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008; 7: 2591-2600.
32. Diaz R, Silva J, Garcia JM, et al. Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer. 2008; 47: 794-802.
33. Han L, Witmer PD, Casey E, Valle D, Sukumar S., DNA methylation regulates MicroRNA expression. Cancer Biol Ther. 2007; 6: 1284-1288. (Pubitemid 351590384)
34. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 2009; 69: 4443-4453.
35. Huang YW, Liu JC, Deatherage DE, et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res. 2009; 69: 9038-9046.
36. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J., Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008; 68: 2094-2105. (Pubitemid 351521781)
37. Ando T, Yoshida T, Enomoto S, et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer. 2009; 124: 2367-2374.
38. Bandres E, Agirre X, Bitarte N, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer. 2009; 125: 2737-2743.
39. Langevin SM, Stone RA, Bunker CH, Grandis JR, Sobol RW, Taioli E., MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis. 2010; 31: 864-870.
40. Smrt RD, Szulwach KE, Pfeiffer RL, et al. MicroRNA miR-137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1. Stem Cells. 2010; 28: 1060-1070.
41. Tarantino C, Paolella G, Cozzuto L, et al. miRNA 34a, 100, and 137 modulate differentiation of mouse embryonic stem cells. Faseb J. 2010; 24: 3255-3263.
42. Shomron N., MicroRNAs and pharmacogenomics. Pharmacogenomics. 2010; 11: 629-632.
43. Szulwach KE, Li X, Smrt RD, et al. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J Cell Biol. 2010; 189: 127-141.
44. Shah JP, Karnell LH, Hoffman HT, et al. Patterns of care for cancer of the larynx in the United States. Arch Otolaryngol Head Neck Surg. 1997; 123: 475-483. (Pubitemid 27212842)
45. Takes RP., Staging of the neck in patients with head and neck squamous cell cancer: imaging techniques and biomarkers. Oral Oncol. 2004; 40: 656-667. (Pubitemid 38686901)
46. Wendt TG, Bank P., Prognostic factors in squamous cell carcinoma of the head and neck. Onkologie. 2002; 25: 208-212. (Pubitemid 34765267)
47. Sieczka E, Datta R, Singh A, et al. Cancer of the buccal mucosa: are margins and T-stage accurate predictors of local control ? Am J Otolaryngol. 2001; 22: 395-399. (Pubitemid 33098077)
48. Smeele LE, Leemans CR, Langendijk JA, et al. Positive surgical margins in neck dissection specimens in patients with head and neck squamous cell carcinoma and the effect of radiotherapy. Head Neck. 2000; 22: 559-563. (Pubitemid 30663070)
49. Thabet MH, Talaat M, Rizk AM., Pitfalls in the surgical management of cancer of the larynx and hypopharynx. Otolaryngol Head Neck Surg. 2000; 123: 482-487.
50. D′Agostino RB, D′Agostino RBJ., A suggestion for using powerful and informative tests of normality. Am Stat. 1990; 44: 316-321.
51. Mehta CR, Patel NR., Exact logistic regression: theory and examples. Stat Med. 1995; 14: 2143-2160.
52. Cox DR., Regression models and life tables. J R Stat Soc B. 1972; 34: 187-220.
53. Grambsch PM, Therneau TM., Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81: 515-526.
54. Prencipe M, McGoldrick A, Perry AS, et al. MAD2 downregulation in hypoxia is independent of promoter hypermethylation. Cell Cycle. 2010; 92856-2865.
55. Zhang C, Li H, Wang Y, et al. Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications. J Hepatol. 2010 [Epub ahead of print].
56. Licchesi JD, Herman JG., Methylation-specific PCR., Methods Mol Biol. 2009; 507: 305-323.